Benutzer: Gast  Login
Titel:

Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

Dokumenttyp:
journal article
Autor(en):
Moe, Sharon M; Chertow, Glenn M; Parfrey, Patrick S; Kubo, Yumi; Block, Geoffrey A; Correa-Rotter, Ricardo; Drüeke, Tilman B; Herzog, Charles A; London, Gerard M; Mahaffey, Kenneth W; Wheeler, David C; Stolina, Maria; Dehmel, Bastian; Goodman, William G; Floege, Jürgen; Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*; Santos, J; Najun Zarazaga, C; Marin, I; Garrote, N; Cusumano, A; Peñalba, N; Del Valle, E; Juncos, L; Martinez Saye, J; Lef, L; Al...     »
Abstract:
Patients with kidney disease have disordered bone and mineral metabolism, including elevated serum concentrations of fibroblast growth factor-23 (FGF23). These elevated concentrations are associated with cardiovascular and all-cause mortality. The objective was to determine the effects of the calcimimetic cinacalcet (versus placebo) on reducing serum FGF23 and whether changes in FGF23 are associated with death and cardiovascular events.This was a secondary analysis of a randomized clinical trial...     »
Zeitschriftentitel:
Circulation
Jahr:
2015
Band / Volume:
132
Heft / Issue:
1
Seitenangaben Beitrag:
27-39
Sprache:
eng
Volltext / DOI:
doi:10.1161/CIRCULATIONAHA.114.013876
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/26059012
Print-ISSN:
0009-7322
TUM Einrichtung:
Abteilung für Nephrologie
 BibTeX